{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:38:07Z","timestamp":1777934287968,"version":"3.51.4"},"reference-count":121,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T00:00:00Z","timestamp":1503273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>The proper evaluation of cancer chemotherapy orders is necessary for patients to receive safe and effective treatment. The chemotherapy treatment setting is evolving resulting in hospital pharmacists without extensive oncology training or experience now being responsible for evaluation of chemotherapy orders. The primary objective was to create a step-by-step chemotherapy order evaluation guide with a detailed explanation for each step. The secondary objective was to evaluate non-oncology trained pharmacists' ability to accurately review simulated chemotherapy orders post-education using the guide. A two-page chemotherapy order evaluation guide was created based on an accepted method of chemotherapy order review consisting of the following eight steps: regimen verification, clinical trial protocol verification, body surface area calculation, dose calculation, laboratory values, emesis prophylaxis, adjunctive or supportive care measures, and pharmacy labels. A literature search was performed for each step. A detailed explanation for each step was written as a separate component from the guide to encompass the literature search information and current guidelines in a more comprehensive manner. Non-oncology trained community hospital pharmacists were educated on use of the guide for approximately 30\u2009min. The guide was evaluated using timed simulated chemotherapy orders pre- and post-education consisting of a general chemotherapy order and a carboplatin dosing order. Nineteen pharmacists were tested with simulated chemotherapy orders. A significant difference was detected between the pre- and post-education for both the general chemotherapy (p\u2009=\u20090.00032) order and carboplatin dosing order (p\u2009=\u20090.031).<\/jats:p>","DOI":"10.1177\/1078155217726162","type":"journal-article","created":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T05:30:59Z","timestamp":1503293459000},"page":"25-43","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Creation and evaluation of a cancer chemotherapy order review guide for use at a community hospital"],"prefix":"10.1177","volume":"25","author":[{"given":"Alexandra P","family":"Punke","sequence":"first","affiliation":[{"name":"PGY1 Pharmacy Resident, Pharmacy Department, Blount Memorial Hospital, Maryville, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JA","family":"Waddell","sequence":"additional","affiliation":[{"name":"Professor, College of Pharmacy, University of Tennessee Health Science Center, Knoxville, USA"},{"name":"Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, Maryville, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,8,21]]},"reference":[{"key":"bibr1-1078155217726162","first-page":"17","volume":"31","author":"Attilio RM","year":"1996","journal-title":"Hosp Pharm"},{"key":"bibr2-1078155217726162","first-page":"1213","volume":"33","author":"Gilmore CE","year":"1998","journal-title":"Hosp Pharm"},{"key":"bibr3-1078155217726162","first-page":"1108","volume":"31","author":"Schwarz LR","year":"1996","journal-title":"Hosp Pharm"},{"key":"bibr4-1078155217726162","first-page":"954","volume":"33","author":"Mahoney CD","year":"1998","journal-title":"Hosp Pharm"},{"key":"bibr5-1078155217726162","first-page":"194","volume":"32","author":"Hutcherson DA","year":"1997","journal-title":"Hosp Pharm"},{"key":"bibr6-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/53.7.737"},{"issue":"1","key":"bibr7-1078155217726162","first-page":"S8","volume":"32","author":"Lajeunesse JD","year":"1997","journal-title":"Hosp Pharm"},{"issue":"1","key":"bibr8-1078155217726162","first-page":"S14","volume":"32","author":"Attilio RM","year":"1997","journal-title":"Hosp Pharm"},{"key":"bibr9-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2014.001386"},{"key":"bibr10-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1016\/S1086-5802(16)30346-1"},{"key":"bibr11-1078155217726162","first-page":"52","volume":"4","author":"Solimando DA","year":"1998","journal-title":"J Oncol Pharm Practice"},{"key":"bibr12-1078155217726162","first-page":"292","volume":"40","author":"Waddell J","year":"2000","journal-title":"J Am Pharm Assoc"},{"key":"bibr13-1078155217726162","doi-asserted-by":"publisher","DOI":"10.2174\/157340311799960645"},{"key":"bibr14-1078155217726162","unstructured":"NCCN Clinical Practice Guidelines in Oncology \u2013 Myeloid Growth Factors. V.1.2016, http:\/\/nccn.org\/professionals\/physician_gls\/pdf\/myeloid_growth.pdf (accessed 6 February 2017)."},{"key":"bibr15-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3488"},{"key":"bibr16-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw325"},{"key":"bibr17-1078155217726162","unstructured":"Neulasta [package insert]. Thousand Oaks, CA: Amgen Inc, http:\/\/pi.amgen.com\/\u223c\/media\/amgen\/repositorysites\/pi-amgen-com\/neulasta\/neulasta_pi_hcp_english.ashx (2016, accessed 17 February 2017)."},{"key":"bibr18-1078155217726162","unstructured":"Neupogen [package insert]. Thousand Oaks, CA: Amgen Inc, http:\/\/pi.amgen.com\/\u223c\/media\/amgen\/repositorysites\/pi-amgen-com\/neupogen\/neupogen_pi_hcp_english.ashx (2016, accessed 17 February 2017)."},{"key":"bibr19-1078155217726162","unstructured":"Granix [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc, http:\/\/granixhcp.com\/Pdf\/prescribing-information.pdf (2014, accessed 17 February 2017)."},{"key":"bibr20-1078155217726162","unstructured":"Leukine [package insert]. Bridgewater, NJ: Sanofi-Aventis US LLC, http:\/\/products.sanofi.us\/Leukine\/Leukine.pdf (2013, accessed 17 February 2017)."},{"key":"bibr21-1078155217726162","unstructured":"Zarxio [package insert]. Princeton, NJ: Sandoz Inc, https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=fe707775-a0ae-41b5-a744-28c41889fce8&type=display (2016, accessed 17 February 2017)."},{"key":"bibr22-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0177"},{"key":"bibr23-1078155217726162","first-page":"458","volume":"19","author":"Weiss RB","year":"1992","journal-title":"Semin Oncol"},{"key":"bibr24-1078155217726162","unstructured":"Jevtana [package insert]. Bridgewater, NJ: Sanofi-Aventis US LLC, http:\/\/products.sanofi.us\/jevtana\/jevtana.pdf (2016, accessed 8 February 2017)."},{"key":"bibr25-1078155217726162","unstructured":"Kyprolis [package insert]. Thousand Oaks, CA: Amgen, http:\/\/pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/kyprolis\/kyprolis_pi.ashx (2016, accessed 23 February 2017)."},{"key":"bibr26-1078155217726162","first-page":"1914","volume":"38","author":"Benvenuto JA","year":"1981","journal-title":"Am J Hosp Pharm"},{"key":"bibr27-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4312-970"},{"key":"bibr28-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1993.1184"},{"key":"bibr29-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1310\/hpj5111-888"},{"key":"bibr30-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1310\/hpj5101-35"},{"key":"bibr31-1078155217726162","unstructured":"Taxotere [package insert]. Bridgewater, NJ: Sanofi-Aventis US LLC, http:\/\/products.sanofi.us\/Taxotere\/taxotere.pdf (2015, accessed 8 February 2017)."},{"key":"bibr32-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00395.x"},{"key":"bibr33-1078155217726162","first-page":"13","volume":"5","author":"Bubalo J","year":"2015","journal-title":"J Hematol Oncol Pharm"},{"key":"bibr34-1078155217726162","unstructured":"Methotrexate [package insert]. Lake Forest, IL: Hospira, Inc, https:\/\/pfizerinjectables.com\/sites\/default\/files\/prod\/child\/uspi\/434139.pdf (2015, accessed 9 February 2017)."},{"key":"bibr35-1078155217726162","unstructured":"Leucovorin [package insert]. Kirkland, Quebec: T.M.Pfizer Canada, Inc, http:\/\/pfizer.ca\/sites\/g\/files\/g10017036\/f\/201410\/LederleLeucovorin_CPI_E_141550_24_Sept_2010.pdf (2010, accessed 9 February 2017)."},{"key":"bibr36-1078155217726162","unstructured":"Levoleucovorin [package insert]. Irvine, CA: Spectrum Pharmaceuticals, Inc, http:\/\/fusilev.com\/downloads\/m1-14-1-3-1125-000503-clean.pdf (2011, accessed 17 February 2017)."},{"key":"bibr37-1078155217726162","unstructured":"Ifosfamide [package insert]. North Wales, PA: TEVA Pharmaceuticals USA, Inc, http:\/\/accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/076657s017s021s025lbl.pdf (2015, accessed 8 February 2017)."},{"key":"bibr38-1078155217726162","unstructured":"Mesna [package insert]. Bedford, OH: Bedford Laboratories, http:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Ben%20Venue_Bedford%20Labs\/55390-045-01%20MSN%201G\/5539004501 (2013, accessed 17 February 2017)."},{"key":"bibr39-1078155217726162","unstructured":"Irinotecan [package insert]. New York, NY: Pfizer Injectables, http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=533 (2016, accessed 17 February 2017)."},{"key":"bibr40-1078155217726162","first-page":"523","volume":"33","author":"Egerton N","year":"2008","journal-title":"Pharmacol Ther"},{"key":"bibr41-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0012"},{"key":"bibr42-1078155217726162","unstructured":"Paclitaxel [package insert]. North Wales, PA: TEVA Pharmaceuticals, https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=88d7cdd2-e650-4a16-adec-873927e03e93 (2015, accessed 17 February 2017)."},{"key":"bibr43-1078155217726162","unstructured":"Rituxan [package insert]. South San Francisco, CA: Genentech, Inc, https:\/\/gene.com\/download\/pdf\/rituxan_prescribing.pdf (2016, accessed 17 February 2017)."},{"key":"bibr44-1078155217726162","unstructured":"Alimta [package insert]. Indianapolis, IN: Eli Lily and Company, http:\/\/uspl.lilly.com\/alimta\/alimta.html#pi (2015, accessed 23 February 2017)."},{"key":"bibr45-1078155217726162","unstructured":"ISMP [Internet]. Horsham (PA): Institute for Safe Medication Practices; c2017. Death and neurological devastation from intrathecal vinca alkaloids: Prepared in syringes\u2009=\u2009120; prepared in minibags\u2009=\u20090, https:\/\/ismp.org\/newsletters\/acutecare\/showarticle.aspx?id=58 (5 September 2013, cited 23 February 2017)."},{"key":"bibr46-1078155217726162","unstructured":"Avastin [package insert]. South San Francisco, CA: Genetech, Inc, https:\/\/gene.com\/download\/pdf\/avastin_prescribing.pdf (2016, accessed 8 February 2017)."},{"key":"bibr47-1078155217726162","unstructured":"Cyramza [package insert]. Indianapolis, IN: Eli Lilly and Company, http:\/\/uspl.lilly.com\/cyramza\/cyramza.html (2016, accessed 3 March 2017)."},{"key":"bibr48-1078155217726162","unstructured":"Cometriq [package insert]. South San Francisco, CA: Exelixis, http:\/\/cometriq.com\/downloads\/Cometriq_Full_Prescribing_Information.pdf (2016, accessed 3 March 2017)."},{"key":"bibr49-1078155217726162","unstructured":"Inlyta [package insert]. New York, NY: Pfizer Labs, http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=759 (2014, accessed 3 March 2017)."},{"key":"bibr50-1078155217726162","unstructured":"Lenvima [package insert]. Woodcliff lake, NJ: Eisai, http:\/\/lenvima.com\/pdfs\/prescribing-information.pdf (2016, accessed 3 March 2017)."},{"key":"bibr51-1078155217726162","unstructured":"Sutent [package insert]. New York, NY: Pfizer Labs, http:\/\/labeling.pfizer.com\/showlabeling.aspx?id=607 (2015, accessed 3 March 2017)."},{"key":"bibr52-1078155217726162","unstructured":"Votrient [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, https:\/\/pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/votrient.pdf (2016, accessed 3 March 2017)."},{"key":"bibr53-1078155217726162","unstructured":"Zaltrap [package insert]. Bridgewater, NJ: Sanofi-Aventis US LLC, http:\/\/products.sanofi.us\/zaltrap\/zaltrap.html (2016, accessed 3 March 2017)."},{"key":"bibr54-1078155217726162","doi-asserted-by":"publisher","DOI":"10.2146\/sp150001"},{"key":"bibr55-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21442"},{"key":"bibr56-1078155217726162","volume-title":"Guide to Cancer Therapeutic Regimens 2014","author":"Adams VR","year":"2014"},{"key":"bibr57-1078155217726162","unstructured":"Cancer Therapy Advisor [Internet]. New York, NY: Haymarket Media, Inc.; 2017 [cited 2017 Mar 1]. Available from: http:\/\/cancertherapyadvisor.com\/."},{"key":"bibr58-1078155217726162","unstructured":"HemOnc.org \u2013 A free hematology\/oncology reference [Internet]. Galloway (NJ): Linode, https:\/\/hemonc.org\/wiki\/Main_Page (2017, cited 1 March 2017)."},{"key":"bibr59-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1887"},{"key":"bibr60-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1191\/1078155203jp107oa"},{"issue":"1022","key":"bibr61-1078155217726162","first-page":"1025","volume":"63","author":"Tamer H","year":"2006","journal-title":"Am J Health Syst Pharm"},{"key":"bibr62-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1023\/B:PHAR.0000026801.14162.3c"},{"key":"bibr63-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt294"},{"key":"bibr64-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2005.04.023"},{"key":"bibr65-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2006.10.010"},{"key":"bibr66-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2005.11.004"},{"key":"bibr67-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.2001.281.3.E586"},{"key":"bibr68-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2013.06.011"},{"key":"bibr69-1078155217726162","unstructured":"Adult Obesity Prevalence Maps [Internet]. Atlanta (GA): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, https:\/\/cdc.gov\/obesity\/data\/prevalence-maps.html (updated 1 September 2016; cited 31 October 2016)."},{"key":"bibr70-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2008.07.005"},{"key":"bibr71-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.108"},{"key":"bibr72-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-199107000-00015"},{"key":"bibr73-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1177\/014107688708001118"},{"key":"bibr74-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.9436"},{"key":"bibr75-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.01.019"},{"key":"bibr76-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1177\/001857870003501005"},{"key":"bibr77-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1177\/1078155215599669"},{"key":"bibr78-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.e19625"},{"key":"bibr79-1078155217726162","unstructured":"US Department of Health and Human Resources. Common Terminology Criteria for Adverse Events (CTCAE), http:\/\/evs.nci.gof\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf (accessed 31 October 2016)."},{"key":"bibr80-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/58.18.1760"},{"key":"bibr81-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.11.1748"},{"key":"bibr82-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"bibr83-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1310\/hpj5002-103"},{"key":"bibr84-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu129"},{"key":"bibr85-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.e13027"},{"key":"bibr86-1078155217726162","first-page":"5","author":"O'Cearbhaill R","year":"2012","journal-title":"Gyn Oncol Group Newsl"},{"key":"bibr87-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-008-0856-x"},{"key":"bibr88-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0012-9"},{"key":"bibr89-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.10.009"},{"key":"bibr90-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1177\/106002807400801104"},{"key":"bibr91-1078155217726162","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443150-00007"},{"key":"bibr92-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008259009500"},{"key":"bibr93-1078155217726162","first-page":"13","volume":"17","author":"Kaag D","year":"2011","journal-title":"Eur J Hosp Pharm"},{"key":"bibr94-1078155217726162","unstructured":"US Food and Drug Administration. Hematology\/oncology (cancer) approvals & safety notifications 2010: carboplatin dosing. US Food and Drug Administration, http:\/\/fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/ucm228974.htm. (accessed 16 November 2016)."},{"key":"bibr95-1078155217726162","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200124010-00003"},{"key":"bibr96-1078155217726162","volume-title":"Drug prescribing in renal failure: dosing guidelines for adults and children","author":"Aronoff GR","year":"2007","edition":"5"},{"key":"bibr97-1078155217726162","unstructured":"Murali AR and Carey WD. Liver test interpretation-approach to patient with liver disease: a guide to commonly used liver tests [Internet]. Lyndhurst, OH: The Cleveland Clinic Foundation, 2014, http:\/\/clevelandclinicmeded.com\/medicalpubs\/diseasemanagement\/hepatology\/guide-to-common-liver-tests\/ (accessed 9 January 2017)."},{"key":"bibr98-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2005.11.002"},{"key":"bibr99-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196205032661802"},{"key":"bibr100-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1001\/jama.239.24.2571"},{"key":"bibr101-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1519"},{"key":"bibr102-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.1118"},{"key":"bibr103-1078155217726162","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-64-2-328"},{"key":"bibr104-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25332"},{"key":"bibr105-1078155217726162","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines \u2013 Antiemesis. V.2.2016, http:\/\/nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf (accessed 31 January 2017)."},{"key":"bibr106-1078155217726162","doi-asserted-by":"crossref","unstructured":"F. Roila, A. Molassiotis, J. Herrstedt, et\u00a0al. MASCC and ESMO Consensus Guidelines for the Prevention of Chemotherapy and Radiotherapy-Induced Nausea and Vomiting: ESMO Clinical Practice Guidelines. On behalf of the participants of the MASCC\/ESMO Consensus Conference Copenhagen 2015.\n                      Ann Oncol\n                      2016; 27(suppl 5): v119-v133.","DOI":"10.1093\/annonc\/mdw270"},{"key":"bibr107-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.3635"},{"key":"bibr108-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.103"},{"key":"bibr109-1078155217726162","unstructured":"Dolasetron [package insert]. Bridgewater, NJ: Sanofi-aventis U.S. LLC, http:\/\/accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020623s009lbl.pdf (2011, accessed 1 February 2017)."},{"key":"bibr110-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515725"},{"key":"bibr111-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1016\/j.suponc.2011.05.002"},{"key":"bibr112-1078155217726162","unstructured":"Palonosetron [package insert]. Switzerland: Helsinn Healthcare SA, http:\/\/aloxi.com\/docs\/pdf\/PI.pdf (2015, accessed 1 February 2017)."},{"key":"bibr113-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.166181"},{"key":"bibr114-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.12.031"},{"key":"bibr115-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-478"},{"key":"bibr116-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1191\/1078155205jp156oa"},{"key":"bibr117-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1191\/1078155202jp093oa"},{"key":"bibr118-1078155217726162","doi-asserted-by":"publisher","DOI":"10.1191\/1078155204jp139oa"},{"key":"bibr119-1078155217726162","doi-asserted-by":"crossref","unstructured":"Sarfati L, Ranchon F, Vantard N, et al. SIMMEON-Prep study: SIMulation of medication errors in ONcology: prevention of antineoplastic preparation errors.\n                      J Clin Pharm Ther\n                      2015; 40: 55\u201362.","DOI":"10.1111\/jcpt.12225"},{"key":"bibr120-1078155217726162","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp050529"},{"key":"bibr121-1078155217726162","unstructured":"<800\u2009>\u2009Hazardous drugs\u2014handling in healthcare settings. USP Compounding Compendium. USP 39-NF 34. First supplement. Rockville, MD: US Pharmacopeial Convention, 2016, pp.85\u2013103."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217726162","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155217726162","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217726162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:17:37Z","timestamp":1777688257000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155217726162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,21]]},"references-count":121,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1177\/1078155217726162"],"URL":"https:\/\/doi.org\/10.1177\/1078155217726162","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,21]]}}}